Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Informatics

Date Submitted: Jul 22, 2021
Open Peer Review Period: Jul 22, 2021 - Jul 30, 2021
Date Accepted: Dec 29, 2021
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning–Based Model Development and Validation

Choi EJ, Jun TJ, Park HS, Lee JH, Lee KH, Kim YH, Lee YS, Kang YA, Jeon M, Kang H, Woo JM, Lee JH

Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning–Based Model Development and Validation

JMIR Med Inform 2022;10(3):e32313

DOI: 10.2196/32313

PMID: 35254275

PMCID: 8938832

Machine learning-based approach to predict long-term survival after allogeneic hematopoietic cell transplantation in hematologic malignancies

  • Eun-Ji Choi; 
  • Tae Joon Jun; 
  • Han-Seung Park; 
  • Jung-Hee Lee; 
  • Kyoo-Hyung Lee; 
  • Young-Hak Kim; 
  • Young-Shin Lee; 
  • Young-Ah Kang; 
  • Mijin Jeon; 
  • Hyeran Kang; 
  • Ji Min Woo; 
  • Je-Hwan Lee

ABSTRACT

Background:

Scoring systems developed for predicting survival after allogeneic hematopoietic cell transplantation (HCT) show suboptimal prediction power, and various factors affect post-transplantation outcomes.

Objective:

A prediction model using a machine learning-based algorithm can be an alternative for concurrently applying multiple variables and reduce potential biases. In this regard, we aimed to establish and validate the machine learning-based predictive model for survival after allogeneic HCT in hematologic malignancies.

Methods:

Data from 1,470 patients with hematologic malignancies who underwent allogeneic HCT between December 1993 and June 2020 at Asan Medical Center were retrospectively analyzed. Using the gradient boosting machine algorithm, we evaluated a model predicting the 5-year post-transplantation survival through 10-fold cross-validation.

Results:

The prediction model showed good performance with a mean area under the receiver operating characteristic curve of 0.788 ± 0.03. Furthermore, we developed a risk score predicting probabilities of post-transplantation survival in 294 randomly selected patients, and an agreement between the estimated predicted and observed risks of overall death, non-relapse mortality, and relapse incidences was observed according to the risk score. Additionally, the calculated score showed the possibility of predicting survival according to the different transplantation-related factors with the visualization of the importance of each variable.

Conclusions:

We developed a machine learning-based model for predicting long-term survival after allogeneic HCT in patients with hematologic malignancies. Our model provides a method for making decisions regarding patient and donor candidates or selecting transplantation-related resources, such as conditioning regimens.


 Citation

Please cite as:

Choi EJ, Jun TJ, Park HS, Lee JH, Lee KH, Kim YH, Lee YS, Kang YA, Jeon M, Kang H, Woo JM, Lee JH

Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning–Based Model Development and Validation

JMIR Med Inform 2022;10(3):e32313

DOI: 10.2196/32313

PMID: 35254275

PMCID: 8938832

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.